1. Home
  2. SSM vs PHGE Comparison

SSM vs PHGE Comparison

Compare SSM & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSM

Sono Group N.V. Ordinary Shares

N/A

Current Price

$7.24

Market Cap

10.4M

Sector

N/A

ML Signal

N/A

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$4.61

Market Cap

9.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSM
PHGE
Founded
N/A
2015
Country
Germany
United States
Employees
43
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
9.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SSM
PHGE
Price
$7.24
$4.61
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
1.7K
142.6K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.34
$0.25
52 Week High
$10.47
$8.50

Technical Indicators

Market Signals
Indicator
SSM
PHGE
Relative Strength Index (RSI) 53.18 47.02
Support Level $6.70 $0.41
Resistance Level $7.50 $6.28
Average True Range (ATR) 0.26 0.88
MACD 0.00 -0.24
Stochastic Oscillator 64.86 27.38

Price Performance

Historical Comparison
SSM
PHGE

About SSM Sono Group N.V. Ordinary Shares

Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: